stockrowImmunovant, Inc.
IMVT Healthcare Biotechnology
- EPS
- −5.63%
- Free cash flow
- −5.96%
Quarter to June 2026, against a year earlier
Follow IMVT
Alert me
Immunovant, Inc. (IMVT) Return on assets
Immunovant, Inc.'s return on assets over the twelve months to 30 June 2026 was −71.1%, down 12.8 percentage points from fiscal 2026 (−58.3%). Over the past ten years it has ranged from −401.9% (fiscal 2019) to −0.01% (fiscal 2018); the current reading is higher than 33% of that period. That is below the Biotechnology industry median of −45.6% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2026 | −58.3% | (0.97) |
| FY2025 | −57.4% | (9.00) |
| FY2024 | −48.4% | (2.58) |
| FY2023 | −45.8% | (12.01) |
| FY2022 | −33.8% | 7.39 |
| FY2021 | −41.2% | 66.59 |
| FY2020 | −107.8% | 294.11 |
| FY2019 | −401.9% | (401.86) |
| FY2018 | −0.01% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | 2.77% |
| PTCT PTC Therapeutics, Inc. compare | −3.62% |
| IONS Ionis Pharmaceuticals, Inc. compare | −18.9% |
| MANE Veradermics Incorporated compare | −20.9% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −21.6% |
| CGON CG Oncology, Inc. compare | −25.1% |
| IMVT Immunovant, Inc. | −71.1% |
| KOD Kodiak Sciences Inc. compare | −94.3% |
| MIRM Mirum Pharmaceuticals, Inc. compare | −99.8% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)